The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...

FRIDAY, Dec. 12, 2025 (HealthDay News) — Less might be more when it comes to immunotherapy treatment of melanoma, a new study ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Medically reviewed by Kristie Reed, PharmD Magnesium and potassium are important for muscle contraction, heart rhythms, and ...

Rezolute sinks after its Phase 3 congenital hyperinsulinism trial showed no statistically significant benefit for ersodetug despite favorable safety data.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...

To access the event by phone, please dial 1-877-317-6789 from the U.S. and Canada or 1-412-317-6789 internationally and ask to be joined into the Rezolute call. The live webcast can be accessed on the ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...